At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pharmacokinetic Interactions Between Buprenorphine and Kaletra (Lopinavir/Ritonavir)
In Brief
A clinical study evaluating Kaletra (lopinavir/ritonavir), buprenorphine, and 1 other intervention for HIV Infections. Completed, enrolled 12 participants across 1 site.
Detailed Summary
The main purpose of this protocol is to study the effect of an HIV medication, Kaletra (lopinavir/ritonavir), on buprenorphine in non-HIV infected people who have been receiving the same dose of buprenorphine for at least 3 weeks. Study Hypothesis: Kaletra (lopinavir/ritonavir) will increase buprenorphine plasma levels without any significant clinical effect on the subject or need for dose adjustment.
Study Details
Timeline
Interventions
4 tablets, once a day (800 mg/dose) on Days 2 through 14 of this study
Buprenorphine will be obtained through prescription at the subject's drug treatment program.
Physical examinations, vital sign measurements, 12-lead electrocardiogram (ECG), clinical laboratory evaluations (blood chemistry and blood counts), PK blood draws.